ArticleFrontiers in neurology2025
Identification of PANoptosis-related genes as biomarkers in ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Mitochondrial Dysfunction Genes as Diagnostic Biomarkers for Ischemic Stroke by Integrated Bioinformatics Analysis and Machine Learning.Journal of molecular neuroscience : MN · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: PANoptosis (panoptotic cell death) is an inflammatory, lytic cell death pathway driven by caspases and RIPKs and regulated by PANoptosome complexes, distinguishing it from other cell death pathways. There is a close potential link between PANoptosis and neuroinflammation, with both regulating each other through complex molecular mechanisms and jointly participating in the pathological processes of neurological diseases. Methods: To investigate whether PANoptosis exists in IS and identify the master regulators of PANoptosis and their relationship. Gene microarray data were downloaded from the Gene Expression Omnibus (GEO) and differentially expressed genes (DEGs) were identified using R software. R software and Cytoscape were used to analyze and visualize the data. Gene ontology-biological process and the Kyoto Encyclopedia of Genes and Genomes were used to analyze the biological processes and possible pathways. The LASSO regression analysis, Random Forest (RF) and support vector machine (SVM) methods were used to identify key genes for diagnostic model construction. In addition, biomarkers with higher diagnostic values for ischemic stroke were validated using other GEO datasets. Results and discussion: Finally, 4,392 upregulated genes and 4,356 downregulated genes were identified in the peripheral blood of 23 normal controls and 69 patients with IS from the GSE58294 dataset. Crossing the differential genes with 277 PANoptosis genes yielded 60 upregulated genes and 58 downregulated genes. The top 10 hub upregulated genes and hub downregulated genes were identified using Cytoscape. Through LASSO regression, RF and SVM, four intersecting genes were screened from upregulated genes, and six intersecting genes were screened from downregulated intersecting genes. These ten intersecting genes were differentially expressed in the validation GSE16561 dataset. The results identify upregulated genes (CASP1, CTNNB1, CASP8) and downregulated genes (PSMC3) as key regulators of PANoptosis in IS. These findings demonstrate that PANoptosis-related genes are differentially expressed in IS and may serve as potential biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.